Fleet MaullThe Entrepreneur’s Zen Master

Clinical trials for PTSD — patgs 26

16 Oct 2026 · 1 min

Watch on YouTube

0:56

In a brief interview, Fleet Maull asks a therapist (Speaker B) about lessons learned from participating in MDMA‑assisted psychotherapy clinical trials for PTSD. The therapist expresses a strong desire to continue providing MDMA therapy, citing robust data on large effect sizes and lasting benefits. They describe the therapeutic process as rewarding, emphasizing the privilege of observing patients form deep emotional connections and confront previously suppressed feelings with minimal therapist intervention. The therapist also laments the tragedy that many individuals who could benefit are unable to access this emerging treatment.

Chapters

What did you learn by participating in those MDMA-assisted psychotherapy clinical trials for PTSD?
That I really want to do MDMA therapy as a therapist. The data's there, right? And I'm sure many people have heard it already before, talking about the effect sizes and the longitudinal benefit. And it's gratifying for the therapist. Of course, the main aim is to be there to help the patient or participant and to be able to watch and not necessarily have to intervene that much and observe the patient or participant make these incredible connections and allow themselves to feel things that maybe have been pushed aside. It's a beautiful, beautiful process to, to observe, and it's tragic for people who hear about this treatment who aren't able to access it.